CellCentric Ltd

CellCentric is a clinical stage biotech company; science driven, patient focused. We lead in the inhibition of p300/CBP to treat specific cancers, notably multiple myeloma. Our aim is to develop our first-in-class drug, inobrodib, as quickly and as effectively as possible for the benefit of patients.

CellCentric is a clinical stage biotech company; science driven, patient focused. We lead in the inhibition of p300/CBP to treat specific cancers, notably multiple myeloma. Our aim is to develop our first-in-class drug, inobrodib, as quickly and as effectively as possible for the benefit of patients. Histone modifying enzymes are targeted, including a methyltransferase, demethylase and a ubiquitin modifying protein. CellCentric’s competitive advantage comes from its relationships with over 30 leading research centres worldwide from which it gains privileged information, from target discovery insights through to clinical relevance and patient data. Validation of the company’s approach has come from business development deals achieved with several major pharmaceutical companies. CellCentric operates internationally with offices in the UK and USA along with multiple research and clinical collaborators, and delivery contractors across the globe. A world leading centre for epigenetics in terms of basic research, innovation and translation. The company is headed by an experienced management team with a track record of building businesses and delivering scientific and financial success.

• Oncology